9.2
Biodisponibilità: Fattori determinanti
La biodisponibilità si riferisce all’estensione e alla velocità con cui un farmaco raggiunge la circolazione sistemica nella sua forma attiva. L’esten…
La biodisponibilità di un farmaco può essere influenzata da diversi fattori.
Le proprietà fisico-chimiche, come la scarsa solubilità, possono ridurre l'assorbimento. Questa limitazione può essere affrontata utilizzando forme a rilascio controllato o con rivestimento enterico.
Anche la stabilità dei farmaci in ambienti gastrici acidi influisce sulla biodisponibilità. I farmaci acido-labili devono essere somministrati come prodotti tamponati o con rivestimento enterico per prevenire la degradazione.
Il metabolismo di primo passaggio riduce significativamente i livelli sistemici di farmaci. Ad esempio, il propranololo subisce un ampio metabolismo, riducendo la sua esposizione sistemica. Nel frattempo, i profarmaci come il valaciclovir vengono metabolizzati in aciclovir, migliorando la biodisponibilità.
Il cibo influisce anche sull'assorbimento dei farmaci. Aumenta i livelli sistemici di isotretinoina ma riduce la biodisponibilità della didanosina.
Infine, le interazioni farmacologiche possono influenzare l'esposizione ai farmaci attraverso enzimi e trasportatori metabolizzatori. Ad esempio, gli inibitori enzimatici aumentano i livelli sistemici rallentando il metabolismo, mentre gli induttori enzimatici lo accelerano, riducendo le concentrazioni plasmatiche dei farmaci.
View the full transcript and gain access to JoVE Core videos
Q1: How do physicochemical properties affect drug bioavailability?
Physicochemical properties like poor solubility significantly decrease drug absorption and reduce bioavailability. Specialized formulations such as controlled-release or enteric-coated forms can address these limitations. For example, Neoral® microemulsion enhances cyclosporine bioavailability compared to conventional formulations by improving dissolution and absorption rates.
Q2: Why does stomach acid reduce the bioavailability of certain drugs?
Acid-labile drugs degrade in the low pH environment of the stomach, significantly reducing bioavailability. Buffered or enteric-coated formulations protect these drugs from gastric acidity, maintaining therapeutic levels. Didanosine uses these strategies to prevent degradation and ensure adequate systemic exposure for therapeutic benefit.
Q3: What is first-pass metabolism and how does it impact drug levels?
First-pass metabolism occurs when drugs are extensively metabolized in the liver during their first pass through portal circulation, significantly reducing systemic availability. Propranolol undergoes extensive first-pass metabolism, reducing its systemic exposure. Prodrugs like valacyclovir bypass this limitation by converting to active forms after absorption, enhancing bioavailability.
Q4: How do food and drug interactions influence bioavailability?
Food can enhance, reduce, or have no significant impact on drug bioavailability. Food increases isotretinoin absorption but reduces didanosine bioavailability. Drug-drug interactions also affect bioavailability through metabolizing enzymes: enzyme inhibitors like ritonavir increase systemic levels by slowing metabolism, while inducers like rifampin accelerate it, reducing plasma concentrations.
Q5: What role do transport proteins play in drug bioavailability?
Transport proteins such as P-glycoprotein significantly influence drug absorption and clearance. Drugs that inhibit or are substrates for transport proteins, like digoxin, show variable bioavailability depending on transporter activity. Understanding transporter interactions is essential for predicting drug exposure and optimizing therapeutic outcomes.
Q6: How do age and disease states affect drug bioavailability?
Aging alters bioavailability through reduced liver mass, decreased perfusion, and declining renal function, potentially increasing drug levels in geriatric patients. Renal and hepatic impairments significantly affect drug elimination: renally excreted drugs show increased bioavailability in kidney dysfunction, while hepatic impairment reduces metabolism, causing systemic drug accumulation.
Q7: What strategies address bioavailability problems in drug formulation?
Multiple strategies overcome bioavailability challenges. Controlled-release and enteric-coated formulations improve solubility and protect from gastric degradation. Prodrug design enhances absorption by converting to active forms post-absorption. Understanding bioavailability enhancement determination and conceptual approaches helps optimize formulations, dosing regimens, and therapeutic outcomes for effective patient care.